Amgen Inc. ($AMGN) Stock Forecast: Down 0.6% Today

What is Amgen Inc.?

Amgen Inc. ($AMGN) is a biotechnology company known for its innovative therapies in areas such as oncology, nephrology, and cardiovascular disease. The company has a strong track record of developing cutting-edge treatments to address unmet medical needs.

Why is Amgen Inc. going down?

AMGN stock is down 0.6% on Mar 31, 2026 15:00

• Amgen experienced a bearish movement despite reporting strong quarterly earnings and positive guidance for the fiscal year. This could be attributed to several factors:
• The market may have reacted negatively to the increased stake acquisitions by Mn Services Vermogensbeheer B.V. and Brookstone Capital Management, possibly signaling concerns about overvaluation or lack of confidence in the company's future performance.
• A recent report on the booming U.S. Rivaroxaban market might have shifted investor focus towards competitors in the cardiovascular space, leading to a sell-off of Amgen shares.
• Analyst warnings about potential setbacks for key launches or competitive pressures from generics in the biotechnology sector could have also contributed to the bearish sentiment surrounding Amgen's stock.
• Despite a recent stake acquisition, the overall market movement may have been influenced by broader industry trends and investor sentiment towards biotech companies rather than individual investment decisions.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

U.S. Rivaroxaban Market Set to Boom Rapidly by 2033 | Pfizer Inc. • Merck & Co. • Amgen Inc

Coherent Market Insights has published a new report detailing the "U.S. Rivaroxaban Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." The report provides a comprehensive analysis of market percentage records, enterprise analysis, competition, geographic distribution, and growth potential, along with economic analysis and anticipated ROI. Major players like Bayer AG, Johnson & Johnson, Pfizer Inc., and Merck & Co. are included, and the report segments the market by cardiovascular disease, atrial fibrillation, venous thromboembolism, and other applications.

https://www.openpr.com/news/4448184/u-s-rivaroxaban-market-set-to-boom-rapidly-by-2033-pfizer-inc

Mn Services Vermogensbeheer B.V. Acquires 3,327 Shares of Amgen Inc. $AMGN

Mn Services Vermogensbeheer B.V. increased its stake in Amgen Inc. by 1.6% during the fourth quarter, acquiring an additional 3,327 shares to hold a total of 208,219 shares valued at approximately $68.15 million. Amgen also reported strong quarterly earnings, beating expectations with $5.29 EPS and $9.87 billion in revenue, and declared a quarterly dividend of $2.52. The stock currently has a "Hold" consensus rating from analysts with an average target price of $354.60.

https://www.marketbeat.com/instant-alerts/filing-mn-services-vermogensbeheer-bv-acquires-3327-shares-of-amgen-inc-amgn-2026-03-31/

Biogen (BIIB) Valuation Check After Mixed Recent Share Returns And Pipeline Driven Undervaluation Narrative

Biogen (BIIB) shares recently closed at US$187.57, with the company having a market value of about US$27.0b. The stock is considered 8.8% undervalued, with a fair value pegged at $205.67, driven by a robust and diversified neurodegenerative and specialty disease pipeline. However, analysts warn that setbacks for key launches or increasing pressure from generics could undermine this valuation.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-biib-valuation-check-after-mixed-recent-share-returns

Financial Planning Hawaii Inc. Takes Position in Amgen Inc. $AMGN

Financial Planning Hawaii Inc. recently acquired a new stake of 6,180 shares in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, valuing the position at approximately $2.02 million. This investment now represents 1.2% of Financial Planning Hawaii Inc.'s portfolio and is its 20th largest holding. Amgen has reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, and has declared a quarterly dividend of $2.52 per share with a 2.9% yield.

https://www.marketbeat.com/instant-alerts/filing-financial-planning-hawaii-inc-takes-position-in-amgen-inc-amgn-2026-03-31/

Brookstone Capital Management Purchases 3,098 Shares of Amgen Inc. $AMGN

Brookstone Capital Management increased its stake in Amgen Inc. by 4.3% in the fourth quarter, acquiring an additional 3,098 shares to reach a total of 74,409 shares worth approximately $24.36 million. Amgen recently reported strong quarterly earnings, surpassing estimates with $5.29 EPS and $9.87 billion in revenue, and set a positive FY2026 guidance. Analysts currently have a "Hold" consensus rating with an average price target of $354.60, though some have raised their targets.

https://www.marketbeat.com/instant-alerts/filing-brookstone-capital-management-purchases-3098-shares-of-amgen-inc-amgn-2026-03-31/

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 8.2% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.2% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 5.4% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Down 5.0% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

Flowserve Corporation ($FLS) Stock Forecast: Up 3.8% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.4% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Down 5.3% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 6.1% Today

Amgen Inc. Price History

31.02.2026 - AMGN Stock was down 0.6%

• Amgen experienced a bearish movement despite reporting strong quarterly earnings and positive guidance for the fiscal year. This could be attributed to several factors:
• The market may have reacted negatively to the increased stake acquisitions by Mn Services Vermogensbeheer B.V. and Brookstone Capital Management, possibly signaling concerns about overvaluation or lack of confidence in the company's future performance.
• A recent report on the booming U.S. Rivaroxaban market might have shifted investor focus towards competitors in the cardiovascular space, leading to a sell-off of Amgen shares.
• Analyst warnings about potential setbacks for key launches or competitive pressures from generics in the biotechnology sector could have also contributed to the bearish sentiment surrounding Amgen's stock.
• Despite a recent stake acquisition, the overall market movement may have been influenced by broader industry trends and investor sentiment towards biotech companies rather than individual investment decisions.

05.10.2025 - AMGN Stock was up 5.3%

• Q3 earnings and revenues for Amgen (AMGN) surpassed expectations, indicating strong financial performance and potentially positive future outlook.
• Despite a slight decline in the current session, the stock has demonstrated resilience over the past month and year, suggesting a reliable long-term investment opportunity.
• Investors are closely monitoring Amgen's Q3 results, particularly focusing on the impact of newer drugs, biosimilar competition, and pricing pressures on the company's growth trajectory.
• The optimistic sentiment surrounding Amgen's financial performance and strategic positioning likely played a role in the bullish movement in the stock today.

05.10.2025 - AMGN Stock was up 7.7%

• Amgen's strong bullish movement today can be attributed to its impressive Q3 earnings and sales beat, surpassing estimates and showcasing double-digit growth driven by key drugs.
• The company's decision to raise its 2025 outlook has instilled confidence in investors, leading to a positive market response.
• Investors are likely encouraged by the company's ability to consistently outperform expectations, as seen in the significant earnings and revenue surprises for the quarter.
• The market's positive reaction also reflects investors' anticipation of Amgen's future performance, as they delve deeper into the company's potential beyond just headline estimates.

07.00.2026 - AMGN Stock was up 5.0%

• Amgen's acquisition of Dark Blue Therapeutics for $840 million, aimed at expanding its oncology pipeline, has instilled optimism among investors regarding the company's strategic growth plans.
• The raise in Amgen's dividend to $2.52 indicates a sustainable payout ratio and a robust earnings growth projection, appealing to income-focused investors and contributing to the stock's performance.
• Comparatively, while Regeneron Pharmaceuticals has had quieter institutional appeal, Amgen's proactive stance in bolstering its portfolio and market standing has garnered positive attention.
• The general bullish outlook on Amgen is also influenced by the optimistic prospects within the broader biotech sector, where investors are acknowledging the potential driven by innovative treatments and strategic acquisitions for future growth.

05.00.2026 - AMGN Stock was down 1.4%

• The decline in Amgen's stock today may be linked to AbbVie's entry into the lung cancer drug market, potentially posing a competitive challenge for Amgen and affecting investor sentiment.
• Despite Amgen's positive quarterly earnings and dividend increase, market reaction might be influenced by the uncertainty surrounding the impact of AbbVie's new drug.
• Sizeable investments from D.A. Davidson & CO., Greenspring Advisors LLC, and Railway Pension Investments Ltd. indicate confidence in Amgen's future outlook. However, market caution could be attributed to the competitive landscape in lung cancer treatments.
• Overall, market sentiment towards Amgen remains optimistic, evident from analyst ratings and price targets. However, today's bearish trend suggests that investors are attentive to evolving competition within the biopharmaceutical sector.

04.01.2026 - AMGN Stock was up 4.3%

• Impressive annual product sales and a dispute with the FDA over Tavneos did not deter investors, as the stock soared to new heights.
• The company's wide economic moat, driven by its innovative drugs in cardiology and immunology, supported the bullish movement.
• Strong financial results for Q4 2025 and the full year, exceeding earnings expectations, along with an optimistic outlook for 2026, fueled investor confidence in Amgen's future growth potential.
• The market's positive reaction to Amgen's performance could also be attributed to the overall bullish sentiment in the biotechnology sector, as evidenced by Ayrmid's breakthrough in stem cell mobilization for gene therapies.

05.01.2026 - AMGN Stock was up 6.1%

• Today's positive movement in Amgen's stock could be a result of favorable investor sentiment following its strong quarterly earnings and increased dividend payout, indicating confidence in its product pipeline.
• The announcement of a SPAC merger by stem cell specialist PrimeGen US may have contributed to a positive market sentiment towards biotech firms, including Amgen, as non-traditional paths to public markets gain attention.
• Despite a maintained Underperform rating by Bank of America, referencing a shifted trial timeline for Amgen, the market appears more focused on the company's strong financial performance and growth prospects, overshadowing immediate concerns.
• Amgen's focus on diverse growth drivers, investments in research and development, and disciplined capital allocation during its recent earnings call likely reassured investors about the company's long-term potential for value creation, driving the positive movement.

06.07.2025 - AMGN Stock was down 5.1%

• Despite surpassing earnings and revenue projections in the second quarter, the stock displayed downward movement.
• The market's reaction may be linked to concerns about the company's future growth potential despite the positive outcomes.
• Investors appear to be capitalizing on gains following a period of robust performance, causing a temporary decline in the stock value.
• Various broader market dynamics such as sector shifts or general market sentiment could be influencing Amgen's stock price negatively.

06.00.2026 - AMGN Stock was up 2.3%

• AMGN's bullish movement can be attributed to its strategic acquisition of Dark Blue Therapeutics, a UK-based cancer drug developer, in a deal worth up to $840 million. This acquisition expands AMGN's oncology portfolio and strengthens its position in the biotechnology industry.
• The acquisition of Dark Blue Therapeutics adds an investigational small molecule targeting specific types of acute myeloid leukemia (AML) to AMGN's pipeline, showcasing the company's commitment to advancing oncology therapeutics.
• The market likely responded positively to the news as the acquisition aligns with AMGN's research focus on targeted protein degradation and leukemia therapeutics, demonstrating its dedication to enhancing its early oncology discovery efforts.
• Additionally, the promising preclinical data on the anti-cancer activity of the MLLT1/3 protein degrader acquired through this deal further fueled investor optimism in AMGN's future growth prospects in the oncology space.

04.01.2026 - AMGN Stock was up 7.4%

• Amgen's bullish movement can be attributed to its impressive Q4 2025 earnings report, exceeding expectations with robust growth across its portfolio and optimistic outlook for 2026.
• The company's refusal to pull the rare disease drug Tavneos from the market, despite FDA concerns, showcases Amgen's confidence in the drug's effectiveness and benefit-risk profile, potentially boosting investor confidence.
• Analysts raising price targets for Amgen indicate continued growth potential, supported by its diversified portfolio and focus on cardiovascular treatments.
• The overall positive sentiment towards Amgen, combined with its strategic growth initiatives and strong financial performance, likely contributed to the stock's bullish movement today.

04.01.2026 - AMGN Stock was up 6.9%

• Amgen's upward trend today is influenced by various factors:
• Analysts have a favorable view of the stock, as evidenced by a higher price target set by Royal Bank of Canada and strong Q4 earnings that surpassed predictions.
• The company's focus on cardiovascular treatments and groundbreaking drugs like Repatha has been instrumental in sustaining free cash flow and fostering growth opportunities.
• Despite a disagreement with the FDA regarding the inflammatory drug Tavneos, Amgen's substantial annual product sales demonstrate its resilience in the industry.
• Amgen's optimistic prospects are further supported by its broad economic moat and strategic position in critical therapeutic areas.

01.09.2025 - AMGN Stock was up 5.3%

• A noteworthy expansion of $650 million was unveiled by Amgen for its U.S. manufacturing network, reflecting a bolstered confidence in future growth prospects.
• The stock's bullish trend may be attributed to investors' optimism towards Amgen's strategic decision to enhance manufacturing capacity in response to evolving pharmaceutical tariff policies.
• Notwithstanding a minor market downturn, Amgen's proactive measures to reinforce manufacturing capabilities likely instilled confidence among investors, driving the stock's positive performance.